Holen Sie sich die Stockscreener-App
41.22
2.79%
1.12
Handel nachbörslich:
41.40
0.18
+0.44%
Schlusskurs vom Vortag:
$40.10
Offen:
$40.18
24-Stunden-Volumen:
3.26M
Relative Volume:
1.52
Marktkapitalisierung:
$6.92B
Einnahmen:
$1.56B
Nettoeinkommen (Verlust:
$152.72M
KGV:
45.83
EPS:
0.8994
Netto-Cashflow:
$221.80M
1W Leistung:
+1.50%
1M Leistung:
-10.53%
6M Leistung:
+22.08%
1J Leistung:
+33.83%
1-Tages-Spanne:
$39.71
$41.57
1-Wochen-Bereich:
$38.98
$41.57
52-Wochen-Spanne:
$27.00
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
41.22 | 6.92B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-13 | Fortgesetzt | JP Morgan | Neutral |
| 2026-06-29 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS) - Yahoo Finance
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Form 8K Alkermes plc. For: 21 September By Investing.com - Investing.com Canada
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - Stock Titan
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - PA Media
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise (NASDAQ:ALKS) - Seeking Alpha
Alkermes upgraded to Buy on strong growth, new drug launches, and promising pipeline in CNS disorders. - Pluang
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program - Business Wire
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Responsive Playbooks and the ALKS Inflection - Stock Traders Daily
Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus
Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan
Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com Australia
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com India
Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews
Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Motley Fool
Alkermes Executive Sells 7,576 Shares, Reducing Holdings - Intellectia AI
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus
Rising Star: Goodwin's Heath Ingram - Law360
Rising Star: Goodwin's Heath Ingram - Law360
ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Canada
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 - Yahoo Finance
Alkermes’ investigational narcolepsy treatment improved wakefulness at every dose - Stock Titan
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gaffin David Joseph | Officer |
Oct 02 '26 |
Proposed Sale |
41.03 |
2,034 |
83,455 |
0 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. |
Sep 03 '26 |
Sale |
48.01 |
2,034 |
97,652 |
223,422 |
| Gaffin David Joseph | Officer |
Sep 03 '26 |
Proposed Sale |
48.01 |
2,034 |
97,652 |
0 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Sep 01 '26 |
Option Exercise |
24.59 |
5,000 |
122,950 |
74,389 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Sep 01 '26 |
Sale |
46.99 |
9,000 |
422,874 |
65,389 |
| Hopkinson Craig C. | Officer |
Sep 01 '26 |
Proposed Sale |
46.99 |
9,000 |
422,874 |
0 |
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Aug 17 '26 |
Sale |
49.23 |
7,576 |
372,937 |
102,193 |
| Nichols Christian Todd | Officer |
Aug 17 '26 |
Proposed Sale |
49.23 |
7,576 |
372,937 |
0 |
| snyderman nancy lynn MD | Director |
Aug 03 '26 |
Option Exercise |
46.72 |
44,472 |
2,077,732 |
59,867 |
| snyderman nancy lynn MD | Director |
Aug 03 '26 |
Sale |
50.35 |
44,472 |
2,239,076 |
15,395 |
0.36%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):